{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:15:34Z","timestamp":1791256534987,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for chronic myeloid leukaemia (CML), but cardiovascular (CV) risk and exacerbation of underlying risk factors associated with TKIs have become widely debated. Real\u2010world evidence reveals little application of CV risk factor screening or continued monitoring within UK CML management. This consensus paper presents practical recommendations to assist healthcare professionals in conducting CV screening\/comorbidity management for patients receiving TKIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multidisciplinary panel meeting and two iterative surveys involving 10 CML specialists: five haematologists, two cardio\u2010oncologists, one vascular surgeon, one haemato\u2010oncology pharmacist and one specialist nurse practitioner.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The panel recommended that patients commencing second\u2010\/third\u2010generation TKIs undergo formal CV risk assessment at baseline, with additional investigations and involvement of cardiologists\/vascular surgeons for those with high CV risk. During treatment, patients should undergo CV monitoring, with the nature and frequency of testing dependent on TKI and baseline CV risk. For patients who develop CV adverse events, decision\u2010making around TKI interruption, cessation or change should be multidisciplinary and balance CV and haematological risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The panel anticipates these recommendations will support healthcare professionals in implementing CV risk screening and monitoring, broadly and consistently, and thereby help optimise TKI treatment for CML.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13983","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T06:54:41Z","timestamp":1682492081000},"page":"201-210","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management"],"prefix":"10.1111","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-8220","authenticated-orcid":false,"given":"Dragana","family":"Milojkovic","sequence":"first","affiliation":[{"name":"Hammersmith Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[{"name":"The Royal Brompton Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[{"name":"University Hospital Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Dimitriadou","sequence":"additional","affiliation":[{"name":"Maidstone &amp; Tunbridge Wells  Tunbridge Wells UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satarupa","family":"Choudhuri","sequence":"additional","affiliation":[{"name":"Northern Care Alliance  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Manisty","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust and University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Cheshire","sequence":"additional","affiliation":[{"name":"The Royal Brompton Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Crozier","sequence":"additional","affiliation":[{"name":"Churchill Hospital  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Basker","sequence":"additional","affiliation":[{"name":"Southampton General Hospital  Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Amer","sequence":"additional","affiliation":[{"name":"Pfizer Ltd.  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Purcell","sequence":"additional","affiliation":[{"name":"Pfizer Ltd.  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tan","sequence":"additional","affiliation":[{"name":"Envision Pharma Group  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.73"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.011"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2306"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6620-20"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025874"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","unstructured":"CortesJE le CoutrePD Gambacorti\u2010PasseriniC et al.3076 Long\u2010term cardiac vascular and hypertension safety of bosutinib (BOS) versus imatinib (IMA) for newly diagnosed chronic myeloid leukemia (CML): results from the BFORE trial. Paper presented at: the 62nd ASH Annual Meeting and Exposition.2020Virtual.","DOI":"10.1182\/blood-2020-134912"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16733"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16971"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"issue":"10","key":"e_1_2_9_21_1","first-page":"1385","article-title":"Chronic myeloid leukemia, version 2.2021","volume":"18","author":"Deininger MW","year":"2020","journal-title":"NCCN Clin Pract Guidelines Oncol"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920"},{"key":"e_1_2_9_23_1","volume-title":"Group Techniques for Program Planning: a Guide to Nominal Group and Delphi Processes","author":"Delbecq AL","year":"1975"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.9.3.458"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099"},{"key":"e_1_2_9_26_1","unstructured":"European Medicines Agency.Summary of product characteristics: Glivec Imatinib.2021Accessed July 14 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/glivec-epar-product-information_en.pdf"},{"key":"e_1_2_9_27_1","unstructured":"European Medicines Agency.Summary of product characteristics: Tasigna Nilotinib.2021Accessed July 14 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tasigna-epar-product-information_en.pdf"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.028"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13215"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13192"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215543"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2335"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-305693"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020006911"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100968"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1261824"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7000"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T21:08:51Z","timestamp":1703970531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/ejh.13983"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13983","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"2022-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}